Thomas Garner serves as the Executive Vice President and Chief Commercial Officer at ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on developing innovative medicines to address unmet medical needs in central nervous system disorders. In his role, Garner is responsible for overseeing the company's commercial strategy and operations, including sales, marketing, and market access. His leadership has been instrumental in the successful launch and growth of ACADIA's flagship product, NUPLAZID, which is used to treat hallucinations and delusions associated with Parkinson's disease psychosis. Garner brings a wealth of experience to ACADIA, with over 25 years in the pharmaceutical industry. Prior to joining ACADIA in 2014, he held various leadership positions at major pharmaceutical companies, including Amgen, where he served as Vice President of Sales and Marketing for the nephrology and oncology divisions. At Amgen, Garner played a key role in the successful launch of several blockbuster drugs, demonstrating his ability to develop and execute effective commercial strategies. He also spent time at Eli Lilly and Company, where he gained valuable experience in sales, marketing, and business development. Under Garner's leadership, ACADIA has made significant strides in expanding its commercial footprint and building a strong foundation for future growth. His strategic vision and deep understanding of the CNS market have been crucial in navigating the complex landscape of drug development and commercialization. Garner's commitment to improving the lives of patients with serious mental health conditions aligns perfectly with ACADIA's mission, making him an invaluable asset to the company as it continues to innovate and bring new treatments to market.